Reduced-intensity, risk factor–stratified immunosuppression for acquired hemophilia A: single-center observational study

Christiane Dobbelstein1 · Georgios Leandros Moschovakis1 · Andreas Tiede1

Received: 2 June 2020 / Accepted: 15 June 2020 / Published online: 3 July 2020 © The Author(s) 2020

Abstract

Immunosuppressive therapy (IST) is administered to patients with acquired hemophilia A (AHA) to eradicate autoantibodies against coagulation factor VIII (FVIII). Data from registries previously demonstrated that IST is often complicated by adverse events, in particular infections. This pilot study was set out to assess the feasibility of reduced-intensity, risk factor–stratified IST. We followed a single-center consecutive cohort of twenty-five patients with AHA receiving IST according to a new institutional treatment standard. Based on results from a previous study, GTH-AH 01/2020, patients were stratified into “poor risk” (FVIII < 1 IU/dl or inhibitor ≥ 20 Bethesda units (BU/ml) or “good risk” (FVIII ≥ 1 IU/dl and inhibitor < 20 BU/ml). Outcomes were compared between the current cohort and the GTH registry as a historic control (n = 102). Baseline characteristics of the cohort were not different from the historic control. Partial remission, defined as FVIII recovered to > 50 IU/dl, was achieved by 68% of patients after a median time of 112 days, which was lower and significantly later than in the historic control (hazard ratio: 1.8, 95% confidence interval 1.2–2.8). Complete remission, overall survival, and frequency of fatal infections were not different. Grade 3 and 4 infections were more frequent. The impact of risk factors that was observed in the historic cohort was no longer apparent, as partial and complete remission and overall survival were similar in “good risk” and “poor risk” patients. In conclusion, reduced-intensity, risk factor–stratified IST is feasible in AHA but did not decrease the risk of infections and mortality in this cohort.

Keywords Factor VIII · Inhibitor · Steroids · Dexamethasone · Rituximab · Cyclophosphamide

Introduction

Acquired hemophilia A (AHA) is an autoimmune disorder. Autoantibodies formed against coagulation factor VIII (FVIII) cause a severe impairment of hemostasis [1–3]. It is usually recommended to administer immunosuppressive therapy in patients with AHA to induce remission of the disease. Glucocorticoids, cyclophosphamide, and rituximab, or combinations thereof, are frequently used for immunosuppression in AHA [4].

Patients not receiving immunosuppression can also achieve remission, but this outcome is not predictable. In a single-center cohort reported in 1987, Lottenberg et al. observed spontaneous remission in 5 out of 16 patients after up to 2 years [5]. However, two patients died from hemorrhage during this time. Cases of late fatal bleeding (3 patients > 100 days after diagnosis) were also observed in the 2007 UK surveillance study [6]. These observations resulted in international recommendations to treat all patients with AHA with immunosuppressive therapy, regardless of their initial bleeding tendency, FVIII activity, or inhibitor titer [1, 7]. From 2010 to 2013, the German, Austrian and Swiss Thrombosis and Hemostasis Society (GTH) study group used a standardized regimen, that was designed based on the 2009 International Recommendation by Huth-Kühne et al. [7], and collected outcomes in a multicenter observational study [8–10]. The GTH-AH 01/2010 cohort was unique because of its prospective observational design, enrolling patients within 7 days after treatment start and securing that information about survival, remission, and adverse events were...
collected in all patients. Possibly as a result of its design, the mortality rate of 34% observed in this study was one of the highest ever reported in AHA. It was noted that mortality due to IST-related infection was the most frequent cause of death (16%) and exceeded the mortality from bleeding (3%) [9]. A similar observation was made in the French SASHA registry published in 2013 [11]. Based on these results, immunosuppressive regimens were identified as an important field of future research. More recent expert recommendations put more emphasis on preventing side effects by suggesting caution in frail patients [2].

The GTH study group had observed FVIII activity and inhibitor titer at the time of diagnosis as prognostic factors for remission and survival [9]. While an impact of these factors on remission was straightforward, their impact on survival was remarkable. The effect did not appear to result from increased bleeding in patients with low FVIII or high inhibitor titers, but rather from longer time of immunosuppressive drug exposure in such patients.

It was considered particularly important that patients with baseline FVIII ≥ 1 IU/dl and inhibitor titer < 20 BU/ml (“good risk”), comprising about one-third of the GTH cohort, had a > 50% chance of achieving PR with glucocorticoids alone within the first 3 weeks. Patients not belonging to this group (FVIII < 1 IU/dl or inhibitor titer ≥ 20 BU/ml, “poor risk”) had a < 10% chance of achieving PR after 3 weeks of steroids. It was therefore considered by the group to stratify patients according to prognostic factors and to administer more intense treatment in “poor risk” patients up front.

In addition, it was believed that the prolonged exposure to glucocorticoids, as implied by the original GTH protocol, could be a major cause of infection and other morbidity. Steroid pulse therapy as compared with continuous exposure could possibly result in fewer side effects while preserving efficacy. This idea was supported by data from other autoimmune disorders such as immune thrombocytopenia. A Chinese randomized controlled trial compared dexamethasone 40 mg/day for 4 days (repeated after 2 weeks in non-responders) with prednisone 1 mg/kg daily (4 weeks) [12]. Dexamethasone resulted in a significantly higher rate of initial response (82% vs. 67%) and complete response (50% vs. 27%). Dexamethasone pulse therapy was also associated with less frequent infection (0% vs. 3%), body weight gain (0% vs. 10%), edema (0% vs. 4%), and Cushingoid appearance (0% vs. 13%).

Based on GTH study results and this additional information, that both became available by 2015, we designed a modified immunosuppressive regimen for AHA comprising dexamethasone pulse therapy and risk-stratified, earlier administration of rituximab (Fig. 1). The regimen was used since 2015 as an institutional treatment standard. Here we report our observations in 25 consecutive patients and compare outcomes to data from the GTH-AH 01/2010 study.

Methods

Study populations

Current cohort

The current study was a single-center, prospective, observational study of consecutive patients with AHA, defined by the presence of a neutralizing factor VIII inhibitor ≥ 0.6 Bethesda units (BU)/ml and a factor VIII activity < 50 IU/dl. All patients treated between January 2015 and July 2019 were enrolled constituting the intention-to-treat (ITT) population. This population was considered most comparable with the GTH study cohort (see below). Consecutive enrollment of the current cohort was ensured by screening the institutional laboratory database for all patients with positive Bethesda inhibitor tests during the time period. Patients with congenital hemophilia A with or without inhibitors were excluded. Otherwise, no inclusion or exclusion criteria were applied. In an additional analysis, only those patients receiving therapy fully adherent to the institutional standard were assessed as the per protocol (PP) population. The research protocol was approved by the institutional ethics committee.

GTH-AH 01/2010 cohort

The historic control population consisted of the multicenter, prospective, observational GTH-AH 01/2010 study enrolling patients with AHA between April 2010 and April 2013 [9]. Inclusion and exclusion criteria of this study were identical to the current study.

Treatment

An overview of the immunosuppressive treatment regimens is provided in Fig. 1.

Current cohort

According to our institutional treatment standard, baseline laboratory data, obtained usually at the day of diagnosis or referral to our institution, were used to stratify patients into “good risk” (factor VIII activity ≥ 1 IU/dl and inhibitor < 20 BU/ml) or “poor risk” (factor VIII activity < 1 IU/dl or inhibitor ≥ 20 BU/ml). Treatment consisted of oral dexamethasone 40 mg per day on 4 consecutive days in weeks 1, 2, 5, and 6 (all patients); intravenous rituximab 375 mg/m² body surface area (BSA) in weeks 1 to 4 (poor-risk patients) or 3 to 6 (good-risk patients); and intravenous cyclophosphamide 750 mg/m² BSA in weeks 5 and 7 (poor risk) or 8 and 10 (good risk). Therapy was stopped as soon as patients achieved partial remission (see below). There was no tapering of the glucocorticoid.
Treatment in the GTH study was based on a consensus protocol developed in 2010. It consisted of daily oral prednisolone (75 mg for patients < 60 kg, 100 mg for 60–100 kg, 150 mg for > 100 kg body weight) in weeks 1 to 10; daily oral cyclophosphamide (100 mg for < 60 kg, 150 mg for 60–100 kg, 200 mg for > 100 kg) in weeks 4 to 6; and intravenous rituximab (375 mg/m² BSA) in weeks 7 to 10.[9] Treatment escalation was withheld if a steady increase of factor VIII activity was observed during 7 days before starting cyclophosphamide or rituximab. If partial remission was achieved, cyclophosphamide and rituximab were stopped, if applicable, and prednisolone was tapered over 6 weeks (descending daily doses of 50, 25, 20, 15, 10, 5 mg for 1 week each).

Endpoints

The definition of endpoints was identical to publications of the GTH-AH 01/2010 study:[9] Partial remission was defined as factor VIII activity restored to > 50 IU/dl and no active bleeding after stopping any hemostatic drug for > 24 h. Complete remission was defined as partial remission plus negative inhibitor test, prednisolone tapered to < 15 mg/day (only applicable for the GTH study), and any other immunosuppressive drug stopped. Additional endpoints were overall survival and frequency of grade 3 and 4 infections.

Statistical analysis

The day of starting glucocorticoid therapy was defined as day 1 for consistency with the GTH study reports. Medians and ranges or interquartile ranges (IQR), or patient/event numbers and frequencies were used to describe data. Frequencies were compared using Fisher’s exact or chi square tests. Time to partial or complete remission and overall survival were assessed using Kaplan Meier analysis and Cox regression analysis. A P value < 0.05 was considered statistically significant for all analyses.

Results

The current cohort consisted of twenty-five patients with AHA. Table 1 provides baseline characteristics of the cohort compared with the GTH-AH 01/2010 cohort, that was used as a historic control for our study. There were no significant differences between the two cohorts, although patients in the current cohort tended to be older (median age 79 vs. 74 years), were more often female (64 vs. 42%), and had more often a poor WHO performance status of score 4 or 5 (36 vs. 16%). The median follow-up time period was 269 days; the total follow-up period was 27 patient-years.

Treatment outcomes are summarized in Table 2 and Fig. 2. Patients of the current cohort achieved partial remission less often (68%) and later (median 112 days) as compared with patients in the historic GTH-AH 01/2010 control (83%, median 36 days). This difference was statistically significant. No difference was observed regarding complete remission or overall survival. Grade 3 or 4 infections affected more patients in the current cohort (64%) as compared with the control (36%).

Patients stratified to “poor risk” (n = 13, 52%) started on rituximab together with glucocorticoids, and four of them were escalated to cyclophosphamide. Patients stratified to...
### Table 1  Demographics and baseline characteristics of the current cohort (ITT population) as compared with the GTH-AH 01/2010 cohort [9]

| Characteristic                  | Current cohort (n = 25) | GTH cohort (n = 102) | P value |
|---------------------------------|-------------------------|----------------------|---------|
| **Gender**                      |                         |                      |         |
| Female, n (%)                   | 16 (64)                 | 43 (42)              | 0.072   |
| Male, n (%)                     | 9 (36)                  | 59 (58)              |         |
| **Underlying disorder**         |                         |                      |         |
| None/idiopathic, n (%)          | 19 (76)                 | 68 (67)              | 0.847   |
| Autoimmunity, n (%)             | 4 (16)                  | 20 (20)              |         |
| Malignancy, n (%)               | 2 (8)                   | 13 (13)              |         |
| Pregnancy, n (%)                | 1 (4)                   | 5 (5)                |         |
| **Concomitant disorders**       |                         |                      |         |
| Coronary artery disease, n (%)  | 6 (24)                  | 28 (27)              | 0.806   |
| Heart failure, n (%)            | 7 (28)                  | 30 (29)              | 1.000   |
| Renal failure, n (%)            | 14 (56)                 | 37 (36)              | 0.110   |
| Arterial hypertension, n (%)    | 17 (68)                 | 59 (58)              | 0.495   |
| Diabetes mellitus type 2, n (%) | 7 (28)                  | 28 (27)              | 1.000   |
| **WHO performance status**      |                         |                      |         |
| 0, n (%)                        | 4 (16)                  | 15 (15)              | 0.087   |
| 1, n (%)                        | 2 (8)                   | 26 (25)              |         |
| 2, n (%)                        | 6 (24)                  | 23 (23)              |         |
| 3, n (%)                        | 4 (16)                  | 22 (22)              |         |
| 4, n (%)                        | 8 (32)                  | 15 (15)              |         |
| 5, n (%)                        | 1 (4)                   | 1 (1)                |         |
| **Age in years—median (range)**| 79 (35–94)              | 74 (26–97)           | 0.130   |
| **Body weight in kg—median (IQR)**| 70 (64–87)            | 77 (69–85)           | 0.234   |
| **Factor VIII activity in IU/dl—median (IQR)** | 2.8 (< 1–7) | 1.4 (< 1–4) | 0.080   |
| **Inhibitor in Bethesda units/ml—median (IQR)** | 14 (4–47) | 19 (7–72) | 0.208   |
| **Risk category**               |                         |                      |         |
| Good, n (%)                     | 12 (48)                 | 37 (36)              | 0.360   |
| Poor, n (%)                     | 13 (52)                 | 65 (64)              |         |

*† Good risk: factor VIII activity ≥ 1 IU/dl and inhibitor < 20 BU/ml. Poor risk: factor VIII activity < 1 IU/dl or inhibitor ≥ 20 BU/ml*

### Table 2  Main outcomes of the current cohort (ITT population) as compared with the GTH-AH 01/2010 cohort

| Outcome                          | Current cohort (n = 25) | GTH cohort (n = 102) | P value |
|----------------------------------|-------------------------|----------------------|---------|
| **Partial remission**            |                         |                      |         |
| Achieved, n (%)                  | 17 (68)                 | 85 (83)              |         |
| Median time to achievement, days (range) | 112 (8–339)        | 36 (7–362)           | 0.021   |
| Hazard ratio (unadjusted, 95% CI)| 1.8 (1.2–2.8)           |                      |         |
| **Complete remission**           |                         |                      |         |
| Achieved, n (%)                  | 17 (68)                 | 43 (42)              |         |
| Median time to achievement, days (range) | 112 (41–339)     | 71 (26–588)          | 0.294   |
| Hazard ratio (unadjusted, 95% CI)| 1.3 (0.8–2.2)           |                      |         |
| **Overall survival**             |                         |                      |         |
| Deceased, n (%)                  | 9 (36)                  | 34 (33)              |         |
| Hazard ratio (unadjusted, 95% CI)| 0.9 (0.4–1.9)           |                      |         |
| **Infections**                   |                         |                      |         |
| Patients with grade 3 and 4 events, n (%) | 16 (64)              | 37 (36)              | 0.014   |
| Patients dying from infection, n (%) | 2 (8)                  | 16 (16)              | 0.523   |

P values are derived from log-rank (Mantel-Cox) test
“good risk” \((n = 12, 48\%)\) started on glucocorticoids alone; six of them were escalated to rituximab, and one later on to cyclophosphamide. Figure 3 shows time to partial and complete remission and overall survival according to risk category within the current cohort. The difference between “good risk” and “poor risk” patients, that had been seen in the GTH study, was not apparent in the current cohort.

To assess the potential impact of protocol deviations, individual immunosuppressive treatments were revisited for each patient. It was found that two patients did not receive immunosuppressive therapy because they were in very poor condition. Seven patients started on prednisolone instead of dexamethasone. No deviations from the institutional standard were noted in the other patients. Figure 4 provides a comparison between the ITT and PP populations that did not show any differences in the likelihood of achieving endpoints.

**Discussion**

The modified immunosuppressive regimen examined in this study differed from the GTH-AH 01/2010 protocol in several aspects:
Dexamethasone pulse therapy instead of continuous prednisolone.

- Lower overall glucocorticoid exposure.
- Intravenous cyclophosphamide pulses instead of continuous oral cyclophosphamide.
- Rituximab before cyclophosphamide in the escalation sequence.
- Early combination therapy (steroid/rituximab) in poor-risk patients.

Stratification according to baseline prognostic factors eliminated the difference in time to remission between “good risk” and “poor risk” patients, that was previously observed in the GTH study. Although the up-front use of rituximab in “poor risk” patients can be seen as an intensification of treatment compared with the historic GTH protocol, it was probably compensated by the reduced exposure to glucocorticoids. The net effect seemed to have been a reduced intensity of immunosuppression in most patients, as supported by the longer time to achieve partial remission.

Although our study showed that reduced-intensity, risk-stratified immunosuppressive therapy is feasible, it also dampened the expectation that this approach could dramatically improve patient-relevant outcomes in AHA. We did not observe fewer infections or improved mortality. This could be explained, in part, with the overall longer exposure to immunosuppressive drugs in our patients. It should be remembered that achieving partial remission defined the end of immunosuppressive regimen, both here and in the GTH study, and that a longer time to this endpoint results in longer exposure to treatment. Furthermore, only the dosing of steroids was significantly reduced here, while the dose of rituximab was still quite high. Reduced doses of rituximab have been used without loss of efficacy in low-risk patients with autoimmune hemolytic anemia [13] and also in AHA [14].

On the other hand, several limitations of our study should be recognized. The size of our single-center cohort is limited, not surprising given the rarity of the disorder. However, we considered the present analysis as an important pilot study before implementing a modified protocol as part of future GTH multicenter study activities. Longer enrolment time was not considered feasible or useful in light of the results reported here. With the GTH-AH 01/2010 study cohort, we chose the best available control group for our analysis. However, some differences between the two cohorts were observed, including non-significant trends towards more advanced age and more frequent female gender of patients. Despite such important limitations, the rates of infection and mortality observed here are a clear indication that the current protocol cannot be expected to achieve dramatic improvements in the management of AHA. Therefore, we believe it is worthwhile to publish our data at this point in time.

The outcomes of our study should also be discussed in a broader context of AHA management. The intention of immunosuppression is generally to eliminate the risk of future bleeding by eradicating the inhibitor [15]. This is necessary because an effective hemostatic prophylaxis against bleeding has not been established. The short half-life of recombinant factor VIIa is limiting the use of this agent in prophylaxis. Activated prothrombin complex concentrate has been used for secondary prophylaxis with an apparent reduction in bleeding [16, 17]. However, this approach may require several infusions per week, probably not feasible in many AHA patients over prolonged periods of time. Recombinant porcine FVIII does not appear to be an appropriate option neither, because of de novo formation of anti-porcine inhibitors [18].
Thus, the currently used agents for treatment of acute bleeds do not seem to be very useful for long-term prophylaxis in AHA.

Non-factor replacement therapies (NFRT), recently studied in congenital hemophilia with inhibitors, could be interesting candidates for long-term prophylaxis in AHA. These include the FVIIIa-mimetic bispecific antibody emicizumab, several anti-tissue factor pathway inhibitor antibodies (conczumab, marstacimab), and the antithrombin-directed siRNA fitusiran [19]. Efficacy and safety of these treatments have been studied, or are still under investigation, in congenital hemophilia with or without inhibitors. It will not be possible to extrapolate these data to patients with AHA, who are usually much older than congenital hemophilia patients, have multiple comorbidities and poor physical performance. The use of emicizumab has occasionally been reported in AHA [20–22], and prohemostatic effects have been documented in ex vivo spiking studies of samples from AHA [23]. However, the slow accumulation of emicizumab with the current subcutaneous dosing regimens and its long plasma half-life create questions on the use in AHA that need to be addressed by well-designed clinical trials.

In summary, IST is still associated with significant side effects, morbidity, and mortality in patients with AHA. The reduced-intensity, stratified regimen that was examined in our single-center observational study appears feasible and resulted in similar results comparing “good risk” and “poor risk” patients. Compared with historic data from the GTH study, our regimen resulted in prolonged time to partial remission but otherwise similar outcomes. Therefore, a significant medical need remains to reduce the risk of bleeding in AHA without the burden of current immunosuppressive regimens.

**Authors’ contributions** AT designed the study and wrote the manuscript. CD and GLM collected data and performed the analysis. All authors approved of the final manuscript.

**Funding Information** Open Access funding provided by Projekt DEAL.

**Compliance with ethical standards** The research protocol was approved by the institutional ethics committee.

**Conflict of interest** The authors declare that they have no conflicts of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Collins P, Chalmers E, Hart D, Jennings I, Liesner R, Rangarajan S, Talks K, Williams M, Hay C (2013) Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol 162(6):758–773. https://doi.org/10.1111/bjh.12463

2. Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebel P, Leissinger CA, Tiede A, Kessler CM (2017) Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol 92(7):695–705. https://doi.org/10.1002/ajh.24777

3. Tie de A, Collins P, Knoebel P, Tietel J, Kessler C, Shima M, Di Minno G, d’Oiron R, Salaj P, Jimenez-Yuste V, Huth-Kuhne A, Giangrande P (2020) International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. https://doi.org/10.3324/haematol.2019.230771

4. Tie de A, Scharf RE, Dobbelstein C, Werwitzke S (2015) Management of acquired haemophilia A. Hamostaseologie 35(4):311–318. https://doi.org/10.5482/HAMO-14-11-0064

5. Lottenberg R, Knetros TB, Kitchens CS (1987) Acquired hemophilia A. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 147(6):1077–1081

6. Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, Keeling DM, Liesner R, Brown SA, Hay CR, Organisation UKHCD (2007) Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 109(5):1870–1877. https://doi.org/10.1182/blood-2006-06-029850

7. Huth-Kuhne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Levesque H, Castellano ME, Shima M, St-Louis J (2009) International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 94(4):566–575. https://doi.org/10.3324/haematol.2008.001743

8. Tie de A, Huth-Kuhne A, Oldenburg J, Grossmann R, Geisen U, Krause M, Brand B, Alberio L, Klamroth R, Spanagl M, Knobl P (2009) Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland. Ann Hematol 88(4):365–370. https://doi.org/10.1007/s00277-008-0665-7

9. Tie de A, Klamroth R, Scharf RE, Trappe RU, Holstein K, Huth-Kuhne A, Gottstein S, Geisen U, Schenk J, Scholz U, Schilling K, Neumeister P, Miesbach W, Mann er D, Greil R, von Auer C, Krause M, Leimkuhler K, Kalus U, Blumtritt JM, Werwitzke S, Budde E, Koch A, Knobl P (2015) Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 125(7):1091–1097. https://doi.org/10.1182/blood-2014-07-587089

10. Tie de A, Hobauer CJ, Werwitzke S, Knobl P, Gottstein S, Scharf RE, Heinz J, Gross J, Holstein K, Dobbelstein C, Schefflinger F, Koch A, Reipert BM (2016) Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study. Blood 127(19):2289–2297. https://doi.org/10.1182/blood-2015-09-672774

11. Borg JY, Guillet B, Le Cam-Duchez V, Goudemand J, Levesque H, Group SS (2013) Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l’Hemophilie Acquise) registry. Haematologica 19(4):564–570. https://doi.org/10.1111/hae.12138

12. Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, Sang YQ, Bi ZM, Ren CA, Zhou F, Liu GQ, Peng J, Hou M (2016)
High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood 127(3):296–302; quiz 370. https://doi.org/10.1182/blood-2015-07-659656

13. Fattizzo B, Zaninoni A, Pettine L, Cavallaro F, Di Bona E, Barcellini W (2019) Low-dose rituximab in autoimmune hemolytic anemia: 10 years after. Blood 133(9):996–998. https://doi.org/10.1182/blood-2018-12-885228

14. Wermke M, von Bonin M, Gehrisch S, Siegert G, Ehninger G, Platzbecker U (2010) Successful eradication of acquired factor-VIII-inhibitor using single low-dose rituximab. Haematologica 95(3):521–522. https://doi.org/10.3324/haematol.2009.017749

15. Holstein K, Liu X, Smith A, Knobl P, Klamaroth R, Geisen U, Eicher H, Miesbach W, Tiede A (2020) Bleeding and response to hemostatic therapy in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood. https://doi.org/10.1182/blood.2019003639

16. Zanon E, Milan M, Gamba G, Ambaglio C, Saggioaro G, Spiezia L, Montani N, Prandoni P (2015) Activated prothrombin complex concentrate (FEIBA(R)) for the treatment and prevention of bleeding in patients with acquired haemophilia: a sequential study. Thromb Res 136(6):1299–1302. https://doi.org/10.1016/j.thromres.2015.10.032

17. Arokszallasi A, Razso K, Ilonczai P, Olah Z, Bereczky Z, Boda Z, Schlamadinger A (2018) A decade-long clinical experience on the prophylactic use of activated prothrombin complex concentrate in acquired haemophilia A: a series from a tertiary care centre. Blood Coagul Fibrinolysis 29(3):282–287. https://doi.org/10.1097/MBC.0000000000000716

18. Kruse-Jarres R, St-Louis J, Greist A, Shapiro A, Smith H, Chowdary P, Drebes A, Gomperts E, Bourgeois C, Mo M, Novack A, Farin H, Ewenstein B (2015) Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 21(2):162–170. https://doi.org/10.1111/hae.12627

19. Nogami K, Shima M (2019) New therapies using nonfactor products for patients with hemophilia and inhibitors. Blood 133(5):399–406. https://doi.org/10.1182/blood-2018-07-820712

20. Al-Banaa K, Alhillan A, Hawa F, Mahmood R, Zaki A, El Abdallah M, Zimmerman J, Musa F (2019) Emicizumab use in treatment of acquired hemophilia A: a case report. Am J Case Rep 20:1046–1048. https://doi.org/10.12659/AJCR.916783

21. Dane KE, Lindsley JP, Streiff MB, Moliterno AR, Khalid MK, Shanbhag S (2019) Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention. Res Pract Thromb Haemost 3(3):420–423. https://doi.org/10.1002/rth2.12201

22. Mohrle P, Pekrul I, Spannagl M, Sturm A, Singh D, Dechant C (2019) Emicizumab in the treatment of acquired haemophilia: a case report. Transfus Med Hemother 46(2):121–123. https://doi.org/10.1159/000497287

23. Takeyama M, Nogami K, Matsumoto T, Noguchi-Sasaki M, Kitazawa T, Shima M (2020) An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A. J Thomb Haemost. https://doi.org/10.1111/jth.14746

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.